4-(2-(dimethylamino)ethoxy)-2-methoxybenzaldehyde | 1402729-49-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(2-(dimethylamino)ethoxy)-2-methoxybenzaldehyde
• 英文别名: 4-[2-(Dimethylamino)ethoxy]-2-methoxybenzaldehyde；4-[2-(dimethylamino)ethoxy]-2-methoxybenzaldehyde
• CAS: 1402729-49-0
• 化学式: C₁₂H₁₇NO₃
• 分子量: 223.272
• InChiKey: CPTLFOZCLNQMES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-氯氧化吲哚 、 4-(2-(dimethylamino)ethoxy)-2-methoxybenzaldehyde 在 哌啶 作用下， 以 甲醇 为溶剂， 反应 0.5h， 以71%的产率得到5-chloro-3-(4-(2-(dimethylamino)ethoxy)-2-methoxybenzyliden)indolin-2-one
  参考文献：
  名称：

  Modification of a promiscuous inhibitor shifts the inhibition from γ-secretase to FLT-3

  摘要：

  The inhibition of FLT-3 activity is an interesting target for the treatment of acute myeloid leukemia (AML). The serendipitous identification of FLT-3 inhibitors from a CK1/gamma-secretase programme provided compounds with dual inhibitory activity. We analyzed the structure-activity relationship of these inhibitors and derivatized them to arrive at compounds with reduced impact on gamma-secretase activity and enhanced FLT-3 inhibition. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.016
• 作为产物：
  描述：

  4-羟基-2-甲氧基苯甲醛 、 alkaline earth salt of/the/ methylsulfuric acid 在 potassium carbonate 作用下， 反应 12.0h， 生成 4-(2-(dimethylamino)ethoxy)-2-methoxybenzaldehyde
  参考文献：
  名称：

  Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond

  摘要：

  The most prevalent leucine-rich repeat kinase 2 (LRRK2) mutation G2019S is associated with Parkinson's disease (PD). It enhances kinase activity and has been identified in both familial and sporadic cases. Kinase activity was reported to be required for LRRK2 mutants to exert their toxic effects. Hence LRRK2 kinase inhibition may be a promising therapeutic target for PD. Here we report on the discovery and characterization of indolinone based LRRK2 inhibitors. Indolinone 15b, the most potent and selective inhibitor of the present series, is characterized by an IC50 of 15nM against wild-type LRRK2 and 10nM against the LRRK2 G2019S mutant, respectively. Compound 15b was further evaluated in a kinase panel including 46 human protein kinases and in a zebrafish embryo phenotype assay, which enabled toxicity determination in whole organisms.

  DOI：

  10.1016/j.bmcl.2014.08.049

文献信息

• NOVEL PYRAZOLE DERIVATIVE
  申请人：Sugimoto Hachiro

  公开号：US20140088029A1

  公开（公告）日：2014-03-27

  Provided is a novel therapeutic means for Alzheimer's disease. In particular, provided is a compound represented by the following general formula (I): [wherein Ar 1 represents 2-methoxy-4-(2-pyridylmethoxy)phenyl etc. and Ar 2 represents a 1H-indol-6-yl group etc.] or a salt thereof.

  提供了一种治疗阿尔茨海默病的新型治疗手段。具体而言，提供了一种由以下通式（I）表示的化合物：[其中Ar1代表2-甲氧基-4-(2-吡啶甲氧基)苯基等，Ar2代表1H-吲哚-6-基等]或其盐。
• Modification of a promiscuous inhibitor shifts the inhibition from γ-secretase to FLT-3
  作者：Ghislaine Marlyse Okala Amombo、Thomas Kramer、Fabio Lo Monte、Stefan Göring、Matthias Fach、Steven Smith、Stephanie Kolb、Robert Schubenel、Karlheinz Baumann、Boris Schmidt

  DOI：10.1016/j.bmcl.2012.10.016

  日期：2012.12

  The inhibition of FLT-3 activity is an interesting target for the treatment of acute myeloid leukemia (AML). The serendipitous identification of FLT-3 inhibitors from a CK1/gamma-secretase programme provided compounds with dual inhibitory activity. We analyzed the structure-activity relationship of these inhibitors and derivatized them to arrive at compounds with reduced impact on gamma-secretase activity and enhanced FLT-3 inhibition. (C) 2012 Elsevier Ltd. All rights reserved.
• US9399635B2
  申请人：——

  公开号：US9399635B2

  公开（公告）日：2016-07-26
• Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond
  作者：Stefan Göring、Jean-Marc Taymans、Veerle Baekelandt、Boris Schmidt

  DOI：10.1016/j.bmcl.2014.08.049

  日期：2014.10

  The most prevalent leucine-rich repeat kinase 2 (LRRK2) mutation G2019S is associated with Parkinson's disease (PD). It enhances kinase activity and has been identified in both familial and sporadic cases. Kinase activity was reported to be required for LRRK2 mutants to exert their toxic effects. Hence LRRK2 kinase inhibition may be a promising therapeutic target for PD. Here we report on the discovery and characterization of indolinone based LRRK2 inhibitors. Indolinone 15b, the most potent and selective inhibitor of the present series, is characterized by an IC50 of 15nM against wild-type LRRK2 and 10nM against the LRRK2 G2019S mutant, respectively. Compound 15b was further evaluated in a kinase panel including 46 human protein kinases and in a zebrafish embryo phenotype assay, which enabled toxicity determination in whole organisms.